mitoxantrone
mitoxantrone: 13 clinical trials tracked.
mitoxantrone evidence translation
What we can confirm
13 tracked trials
What it means
What to watch
Prepared research question
What is verified about mitoxantrone, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 5 study sponsors
Clinical Trials (13)showing 10 most recent
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
Primary endpoint: Minimal Residual Disease
A Collaboration Phase 2 Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
Primary endpoint: Minimal residual disease (MRD)-negativity rate
A Phase 1/2 Single-Center Trial Combining Venetoclax With G-CSF, Cladribine, Cytarabine, and Mitoxantrone (CLAG-M) for Patients With AML and High-Grade Myeloid Neoplasms
Primary endpoint: Incidence of adverse events (Phase I)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Primary endpoint: Event-free survival (EFS)
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Primary endpoint: 3-month Overall Survival (OS)
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse
Primary endpoint: Percentage of Participants With Complete Response (CR) Rate
A Phase II, Open-label, Single Arm Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Twice Daily Midostaurin (PKC412) Combined With Standard Chemotherapy and as a Single Agent Post-consolidation Therapy in Children With Untreated FLT3-mutated AML
Primary endpoint: Part 1 of the study: Occurence of dose limiting toxicities (DLT)
Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation
Primary endpoint: Overall Survival (OS)
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia - Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination With Induction Chemotherapy
Primary endpoint: Incidence of dose limiting toxicities (DLTs).
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I
Primary endpoint: Percentage of Treatment-related Mortality (TRM)